Japan Esomeprazole Market

Japan Esomeprazole Market Insights Forecasts to 2035.

• Japan Esomeprazole Market Size Was Estimated at USD 149 Million in 2024.
• The Market Size is Expected to Grow at a CAGR of Around 5.83% from 2025 to 2035.
• Japan Esomeprazole Market Size is Expected to Reach USD 278 Million by 2035.

According to a research report published by Spherical Insights & Consulting, Japan Esomeprazole Market size is anticipated to reach USD 278 Million by 2035, Growing at a CAGR of 5.83% from 2025 to 2035. The Japan esomeprazole market is driven by the continuously increasing incidence of gastroesophageal reflux disease (GERD) and peptic ulcer in an experimental population., In a survey conducted by OECD, more than 28 % of Japan people are above 65 years of age, and this value represents the percentage of the population belonging to the geriatric population.

Market Overview

Japan esomeprazole market is a pharmaceutical drug that is classified as a proton pump inhibitor (PPI) and is primarily available as a prescription medicine. It is a first-line drug used for the treatment and maintenance of various gastric acid-related diseases. esomeprazole continues to play a clinically and regionally relevant role in Japan due to its well-established efficacy in gastroesophageal reflux disease (GERD) and ulcer disease prevention, as well as acceptable pharmacokinetics in a patient population with high incidences of CYP2C19 poor metabolizers. Peptic ulcer disease and GERD are the most common sources of demand, characteristic of the ageing population in Japan, the escalated use of NSAIDS, and a lifestyle change towards a highly Westernised diet.

The Japan esomeprazole market is driven by the continuously increasing of gastroesophageal reflux disease (GERD) and peptic ulcer in an experimental population., In a survey conducted by OECD, more than 28 % of Japan people are above 65 years of age, and this value represents the percentage of the population belonging to the geriatric population.

Report Coverage

This research report categorizes the market for the Japan esomeprazole market based on various segments and regions, and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Japan esomeprazole market. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition, have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Japan esomeprazole market.

Driving Factors

The Japan esomeprazole markets in Japan are driven by rising prevalence of gastrointestinal disorders, increasing awareness about acid-related diseases, growing elderly population with higher susceptibility to GERD, and expanding availability of generic and over-the-counter formulations.

Restraining Factors

The Japan esomeprazole market in Japan is restrained by the high cost of production, due to which there is an increase in the overall cost of the end product. Many consumers cannot afford a medicinal product owing to their high cost.

Market Segmentation

The Japan esomeprazole market share is categorized by Indication, drug type and formulation. 

• The GERD segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. 

The Japan esomeprazole market is segmented by Indication into GERD, peptic ulcer, NSAID-Induced ulcer prevention, H. pylori eradication, and others. Among these, the GERD segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. The segmental growth is driven by developments that high prevalence among the ageing population, widespread adoption of Western dietary habits, increased stress-related lifestyle factors, and strong physician preference for proton pump inhibitors in managing acid reflux conditions.

• The branded segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period.  

The Japan esomeprazole market is segmented by drug type into branded, generic. Among these, the branded segment accounted for the largest revenue share in 2024 and is expected to grow at a significant CAGR during the forecast period. The growth of the segment is due to physician and patient trust, strong marketing by domestic companies, government policies encouraging cost-effective alternatives, and the gradual shift from patented drugs to lower-cost branded generic formulations.

• The capsules segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. 

The Japan esomeprazole market is segmented by formulation into tablets, capsules. Among these, the capsules segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. The segmental growth is driven by developments in their superior bioavailability and stability, patient preference for easy swallowing and convenience, wide availability across both branded and generic products, and suitability for controlled or delayed-release formulations that enhance therapeutic effectiveness.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Japan esomeprazole market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• AstraZeneca
• Daiichi Sankyo
• Teva Pharmaceutical Industries
• Amneal Pharmaceuticals
• Viatris
• Sun Pharmaceutical Industries
• Dr Reddy’s Laboratories
• Cadila Pharmaceuticals Ltd.
• Torrent Pharmaceuticals
• Glenmark Pharmaceuticals

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In June 2019, Multiple domestic manufactures (e.g. Towa, Nipro) launched generic esomeprazole formulation under NIH listing .

Market Segment

This study forecasts revenue at the Japan, regional, and country levels from 2020 to 2035. Decision Advisiors has segmented the Japan esomeprazole market based on the below-mentioned segments:

Japan Esomeprazole Market, By Indication

• GERD
• Peptic Ulcer
• NSAID-Induced Ulcer Prevention
• H. pylori Eradication
• Others

Japan Esomeprazole Market, By Drug Type

• Branded
• Generic

Japan Esomeprazole Market, By Formulation

• Tablets
• Capsules

FAQ’s                                                                       

Q: What was the size of the Japan esomeprazole market in 2024?
A:  The Japan esomeprazole market size was estimated at USD 149 million in 2024.

Q: What is the expected market size and growth rate by 2035?
A: The market is projected to reach USD 278 million by 2035, growing at a CAGR of 5.83% from 2025 to 2035.

Q: Which indication segment dominated the market in 2024?
A: The GERD segment held the largest market share in 2024.

Q: What are the main factors driving the Japan esomeprazole market growth?
A: Rising prevalence of gastrointestinal disorders, an ageing population, lifestyle changes toward Western diets, and the growing availability of generic formulations are key growth drivers.